2021
-
Cigarette Sales Up in U.S. for the First Time in 20 Years
October 26, 2021—The U.S. Federal Trade Commission’s (FTC’s) recently released Cigarette Report1 showed that the number of cigarettes sold increased from 202.9 billion in 2019 to 203.7 billion in 2020. […]
-
Intratumoral Dendritic Cells in Treatment of Lung Cancer
In the past decade, targeting of the PD-1/PD-L1 checkpoint, with or without CTLA-4 targeting, has revolutionized cancer treatment. However, a significant proportion of patients with lung cancer still do not […]
-
Studies Question Further Modification of pTNM Staging as 9th Edition Deadline Approaches
Two studies presented at the WCLC Congress 2021 include data that suggest the potential need to update the current TNM classification of lung cancers by implementing additional pathological elements to […]
-
New Warranty, Rebate Programs Put Spotlight on Value in Lung Cancer
Value-based care is getting more attention in lung cancer thanks to two new programs offering significant rebates or full refunds should the therapeutic agent be ineffective or intolerable. Pfizer’s pilot […]
-
Rare NUT Carcinoma Gaining Recognition in Lung Cancer Community
In 2015, the World Health Organization (WHO) revised its 2004 classification of lung tumors to reflect the impact of genetic, clinical, and radiologic advances in the field.1 Among the revisions […]
-
Benefit to Pembrolizumab Observed in Previously Treated Malignant Pleural Mesothelioma Irrespective of PD-L1 Status
Treatment options for patients with malignant pleural mesothelioma (MPM) are limited. While patients with advanced or inoperable MPM are traditionally treated with cisplatin and pemetrexed as a standard first-line treatment, […]
-
Assay that Combines Clinical, Radiomic Characteristics with CT Information Shown to Better Distinguish Malignant Early Lung Nodules
Although low-dose CT scans enable the detection of very small lung nodules in individuals who face a high risk of developing lung cancer, it is often impossible to quickly determine […]
-
Comprehensive Analysis of Proteomics Identifies New, Druggable Drivers of NSCLC—and New Avenue for Continued Research
Despite the past decade’s accomplishments in identifying the genetic drivers of NSCLC, the complexity of these cancers continues to create barriers to effective targeted treatment. Finding strategies capable of overcoming […]
-
Atezolizumab Approved for Adjuvant NSCLC Therapy for Patients with Stage II-IIIA Disease, PD-L1 ≥ 1%
October 15, 2021— Based on the results of phase III IMpower010, atezolizumab was approved by the U.S. Food and Drug Administration (FDA) as adjuvant treatment after surgery and chemotherapy for […]
-
Toward More Inclusive, Accessible Clinical Trial Consent Forms
It is a trend many years in the making, but the time is ripe to fix the increasing problems with clinical trial consent documentation. The word count and complexity of […]
View ILCN Archives
Provider Resources